BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21919027)

  • 1. Ghrelin receptor as a novel imaging target for prostatic neoplasms.
    Lu C; McFarland MS; Nesbitt RL; Williams AK; Chan S; Gomez-Lemus J; Autran-Gomez AM; Al-Zahrani A; Chin JL; Izawa JI; Luyt LG; Lewis JD
    Prostate; 2012 Jun; 72(8):825-33. PubMed ID: 21919027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expressions of the androgen receptor in normal prostate, benign prostatic hyperplasia and prostate cancer].
    Zeng R; Liu ZY; Sun YH; Xu CL; Gao X; Jiao L
    Zhonghua Nan Ke Xue; 2010 Nov; 16(11):967-72. PubMed ID: 21218636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.
    Hormaechea-Agulla D; Gahete MD; Jiménez-Vacas JM; Gómez-Gómez E; Ibáñez-Costa A; L-López F; Rivero-Cortés E; Sarmento-Cabral A; Valero-Rosa J; Carrasco-Valiente J; Sánchez-Sánchez R; Ortega-Salas R; Moreno MM; Tsomaia N; Swanson SM; Culler MD; Requena MJ; Castaño JP; Luque RM
    Mol Cancer; 2017 Aug; 16(1):146. PubMed ID: 28851363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.
    Bauman TM; Becka AJ; Sehgal PD; Huang W; Ricke WA
    Hum Pathol; 2015 Nov; 46(11):1744-51. PubMed ID: 26344417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander?
    Shah R; Mucci NR; Amin A; Macoska JA; Rubin MA
    Am J Pathol; 2001 May; 158(5):1767-73. PubMed ID: 11337374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
    Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
    Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: association with asymptomatic inflammatory prostatitis NIH category IV.
    Engelhardt PF; Seklehner S; Brustmann H; Lusuardi L; Riedl CR
    Scand J Urol; 2015 Apr; 49(2):120-6. PubMed ID: 25363611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines.
    Cassoni P; Ghé C; Marrocco T; Tarabra E; Allia E; Catapano F; Deghenghi R; Ghigo E; Papotti M; Muccioli G
    Eur J Endocrinol; 2004 Feb; 150(2):173-84. PubMed ID: 14763915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical profiles of claudin-3 in primary and metastatic prostatic adenocarcinoma.
    Bartholow TL; Chandran UR; Becich MJ; Parwani AV
    Diagn Pathol; 2011 Jan; 6():12. PubMed ID: 21255442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo steroid biosynthesis in human prostate cell lines and biopsies.
    Sakai M; Martinez-Arguelles DB; Aprikian AG; Magliocco AM; Papadopoulos V
    Prostate; 2016 May; 76(6):575-87. PubMed ID: 26841972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer antigen-1 as a potential novel marker for prostate cancer.
    Liu BQ; Wu YD; Li PH; Wei JX; Zhang T; Liu RL
    Asian J Androl; 2007 Nov; 9(6):821-6. PubMed ID: 17968469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer.
    Mariani S; Salvatori L; Basciani S; Arizzi M; Franco G; Petrangeli E; Spera G; Gnessi L
    J Urol; 2006 Jun; 175(6):2072-7; discussion 2077. PubMed ID: 16697805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
    Zhang L; Guo F; Gao X; Wu Y
    Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymph and blood vessel architecture in benign and malignant prostatic tissue: lack of lymphangiogenesis in prostate carcinoma assessed with novel lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE-1).
    Trojan L; Michel MS; Rensch F; Jackson DG; Alken P; Grobholz R
    J Urol; 2004 Jul; 172(1):103-7. PubMed ID: 15201747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoreactivity of ubiquitin in human prostate gland.
    Bataineh ZM; Habbal O
    Neuro Endocrinol Lett; 2006 Aug; 27(4):517-22. PubMed ID: 16892003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgG gene expression and its possible significance in prostate cancers.
    Liu Y; Chen Z; Niu N; Chang Q; Deng R; Korteweg C; Gu J
    Prostate; 2012 May; 72(6):690-701. PubMed ID: 22430367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of some selected cytokeratins and Ki67 protein in prostatic tumor: can these be used as tumor markers.
    Adisa JO; Egbujo EC; Ibrahim B; Musa B; Madukwe J
    Pan Afr Med J; 2015; 20():46. PubMed ID: 26090004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of proinflammatory cytokine interleukin-6 in tissue samples of human prostate obtained by needle biopsy.
    Miličević N; Mrčela M; Galić J; Marjanović K
    Pathol Res Pract; 2015 Nov; 211(11):865-70. PubMed ID: 26376467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases.
    Brössner C; Petritsch K; Fink K; Auprich M; Madersbacher S; Adlercreutz H; Rehak P; Petritsch P
    Urology; 2004 Oct; 64(4):707-11. PubMed ID: 15491706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.